Celyad Oncology SA (EBR:CYAD)
Belgium · Delayed Price · Currency is EUR 0.2750
-0.0010 (-0.36%)
Jul 22, 2026, 10:10 AM CET
Celyad Oncology Revenue
In the year 2025, Celyad Oncology had annual revenue of 21.00K EUR, down -88.71%. Celyad Oncology had revenue of 7.00K in the half year ending December 31, 2025, a decrease of -87.93%.
Revenue
21.00K
Revenue Growth
-88.71%
P/S Ratio
588.30
Revenue / Employee
4.20K
Employees
5
Market Cap
12.35M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.00K | -165.00K | -88.71% |
| Dec 31, 2024 | 186.00K | 84.00K | 82.35% |
| Dec 31, 2023 | 102.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 5.00K | -1.00K | -16.67% |
| Dec 31, 2019 | 6.00K | -3.11M | -99.81% |
| Dec 31, 2018 | 3.12M | -425.00K | -12.01% |
| Dec 31, 2017 | 3.54M | -4.98M | -58.47% |
| Dec 31, 2016 | 8.52M | 8.52M | 284,000.00% |
| Dec 31, 2015 | 3.00K | -143.00K | -97.95% |
| Dec 31, 2014 | 146.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 54.00K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | 1.52M | -2.12M | -58.32% |
| Dec 31, 2009 | 3.64M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 7.74B |
| argenx SE | 4.11B |
| European Medical Solutions | 52.80M |
| Hyloris Pharmaceuticals | 7.94M |
| Onward Medical | 5.41M |
| Oxurion NV | 555.00K |
| Financière de Tubize | 13.26K |
| BioSenic | -2.39M |
Celyad Oncology News
- 3 months ago - Celyad Oncology Annual report: H2 2025 - Filings
- 10 months ago - Celyad Oncology Earnings release: H1 2025 - Filings